Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.Explore and learn more about Conference Series : World's leading Event Organizer
Multitargetinhibitors, Recent developments in biological systems and overall clinical experience have revealed that the single-target drugs may not always induce the desired effect to the entire biological system even if they successfully inhibit or activate a specific target one reason is that organisms can affect effectiveness through compensatory ways. The development of diseases, particularly the complex ones, involves several aspects. Thus, scientists have recently proposed the multi-target drug design concept,
OMICS International through its Open Access Initiative is committed to make genuine and reliable contributions to the scientific community. OMICS International hosted 9 open access articles Open Access articles, 27 Scientific conference Proceedings, 1 national symposiums and on Key word multi target inhibitors in Global Events page. Global Events of Conference series make the perfect platform for global networking as it brings together renowned speakers and scientists across the globe to a most exciting and memorable scientific event filled with much enlightening interactive sessions, world class exhibitions of OMICS International Conferences.
Market Analysis
Overall sales in the current antibiotics and new products market were nearly $40 billion in 2008. It increased to $41.5 billion in 2009. By 2014 ,it is projected to increase to $65.5 billion, for a 5-year compound annual growth rate (CAGR) of 9.6%.The largest segment antibiotic drugs market was nearly $36 billion in 2008; this further increased to $37 billion in 2009, this projected to reach $50 billion in 2014, for a 5-year CAGR of 5.9%.Sales in the bacterial vaccines market amounted to $3.6 billion in 2008 which increased slightly to $3.9 billion in 2009. This is projected to increase to $15 billion in 2014, for a 5-year CAGR of 31.6%.
Scope and Importance
Numerous pathogens that have become resistant to commonly used antibiotics have been described in various contexts, including drug-resistant methycillin-resistant Staphylococcus aureus (MRSA), Streptococcus pneumoneae, and Mycobacterium tuberculosis. Antibiotics-2015 is the premier event that brings together a unique and International mix of experts, researchers and decision makers from both academia and industry across the globe to exchange their knowledge, experience and research innovations. There is a renewed interest in the antibiotic sector, which is evident from the most recent patents and investments. Bacterial vaccines and new antibiotic classes are gaining a tremendous amount of attention with several product candidates in clinical development. This conference focuses exclusively on antibiotics, bacterial vaccines, and other emerging antibacterial
Associations
Companies:
This page will be updated regularly.
This page was last updated on November 5, 2024
